Cilostazol
▼This medicinal product is subject to additional monitoring. This will allow for the quick
identification of new safety information. The user of the medicinal product can also help by
reporting any adverse reactions that occur after taking the medicinal product. To find out how to
report adverse reactions, see section 4.
Cilozek belongs to a group of medicinal products called phosphodiesterase type 3 inhibitors. The action of the medicinal product
includes the dilation of certain blood vessels and the reduction of the blood clotting process (aggregation) of certain blood cells called platelets.
Cilozek has been prescribed for the treatment of a disease called "intermittent claudication". Intermittent claudication is characterized by the occurrence of painful leg cramps during walking and is caused by insufficient blood supply to the legs. Cilozek allows for an increase in the distance that the patient can walk without pain, thanks to improved blood circulation in the legs. Cilostazol is only recommended for patients who have not responded sufficiently to changes in their lifestyle (such as quitting smoking and increasing physical activity) and other treatment methods. It is essential that the patient continues to make lifestyle changes while taking Cilozek.
Before starting to take Cilozek, the patient should discuss it with their doctor or pharmacist.
The patient should inform their doctor if:
While taking Cilozek:
The patient should tell their doctor or pharmacist about all the medicinal products they are taking, or have recently taken, as well as any medicinal products they plan to take.
In particular, the patient should inform their doctor about taking medicinal products used to treat pain and inflammatory conditions of the muscles and joints, as well as medicinal products that reduce blood clotting.
These medicinal products include:
If the patient needs to take any of the above-mentioned medicinal products at the same time as Cilozek, the doctor may recommend regular blood tests.
Some medicinal products may affect the action of Cilozek if taken at the same time.
They may either increase the risk of adverse reactions to Cilozek or reduce the effectiveness of its action. Similarly, Cilozek may affect the action of other medicinal products.
Before starting to take Cilozek, the patient should inform their doctor if they are taking:
In case of doubts about whether any of the above situations apply to the patient, they should consult their doctor or pharmacist.
Before starting to take Cilozek, the patient should inform their doctor if they are taking medicinal products that lower blood pressure, as Cilozek may have an additional blood pressure-lowering effect. If blood pressure drops too low, it may cause rapid heartbeat. Medicinal products that lower blood pressure include:
In many cases, it is possible to take the above-mentioned medicinal products and Cilozek at the same time.
The doctor will decide which medicinal products the patient can take.
The medicinal product should be taken 30 minutes before breakfast and 30 minutes before the evening meal.
The tablets should always be taken with water.
Cilozek MUST NOTbe used during pregnancy.
IT IS NOT RECOMMENDEDto use Cilozek during breastfeeding.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to become pregnant, they should consult their doctor or pharmacist before taking this medicinal product.
Cilozek may cause dizziness. If the patient experiences dizziness after taking the medicinal product, they MUST NOTdrive or operate tools or machines. They should inform their doctor or pharmacist about this.
This medicinal product should always be taken according to the doctor's instructions. In case of doubts, the patient should consult their doctor or pharmacist.
The recommended dose of the medicinal product is one 100 mg tablet, twice a day (taken as one tablet in the morning and one in the evening). There is no need to modify the dosage in elderly patients.
However, the doctor may reduce the dose of the medicinal product if the patient is taking other medicinal products that affect the action of Cilozek. The medicinal product should be taken 30 minutes before breakfast and 30 minutes before the evening meal. The tablets should always be taken with water.
Sometimes, the benefits of taking Cilozek are noticeable within 4-12 weeks of treatment. After 3 months, the doctor will assess the progress of the treatment and may recommend stopping cilostazol if the treatment effects are insufficient.
Cilozek is not indicated for use in children.
If the patient has taken more tablets of Cilozek than they should, they may experience the following symptoms: severe headache, diarrhea, decreased blood pressure, and heart rhythm disorders.
If the patient misses a dose of Cilozek, they should not worry. They should wait until the time when the next dose is due and take the recommended dose, according to the prescribed dosage regimen. They MUST NOTtake a double dose to make up for the missed dose.
If the patient stops taking Cilozek, the pain in their legs may return or worsen.
For this reason, Cilozek may only be stopped if the patient experiences adverse reactions that require immediate medical attention (see section 4) or if the doctor recommends it.
In case of any doubts about taking this medicinal product, the patient should consult their doctor or pharmacist.
Like all medicinal products, Cilozek can cause adverse reactions, although not everybody gets them.
The frequency of adverse reactions is defined as follows:
Very common: occurs more frequently than in 1 in 10 patients
Common: occurs less frequently than in 1 in 10 patients
Uncommon: occurs less frequently than in 1 in 100 patients
Rare: occurs less frequently than in 1 in 1000 patients
Very rare: occurs less frequently than in 1 in 10,000 patients
Frequency not known: frequency cannot be estimated from the available data.
The patient should also contact their doctor immediately if they experience fever or sore throat.
It may be necessary to perform blood tests, and the doctor will decide on further treatment.
Very common adverse reactions(may occur more frequently than in 1 in 10 patients)
Common adverse reactions(may occur less frequently than in 1 in 10 patients)
Uncommon adverse reactions(may occur less frequently than in 1 in 100 patients)
In patients with diabetes, there may be an increased risk of bleeding into the eyeball.
Rare adverse reactions(may occur less frequently than in 1 in 1000 patients)
If the patient experiences any adverse reactions, including any adverse reactions not listed in the leaflet, they should tell their doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309;
website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions can help gather more information on the safety of the medicinal product.
The medicinal product should be stored out of sight and reach of children.
The medicinal product should not be used after the expiry date stated on the packaging.
The expiry date refers to the last day of the month stated.
There are no special precautions for storage.
Medicinal products should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicinal products they no longer use. This will help protect the environment.
Cilozek, 100 mg tablets, are white or almost white, round, flat tablets with the inscription "100" on one side.
The medicinal product is available in packs of 28, 56 tablets, packaged in PVC/PVDC/Al blisters.
For more detailed information, the patient should consult the marketing authorization holder or parallel importer.
Adamed Pharma S.A.
Pieńków, ul. M. Adamkiewicza 6A
05-152 Czosnów
Poland
Adamed Pharma S.A.
ul. Marszałka Józefa Piłsudskiego 5
95-200 Pabianice
Poland
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:83/176/14-C
Parallel import authorization number:100/18
[Information about the trademark]
Estonia | Cilozek |
Poland | Cilozek |
Czech Republic | Cilozek |
Slovakia | Cilozek 100 mg tablets |
Hungary | Cilozek 100 mg tablets |
Spain | Cilostazol MYLAN 100 mg tablets EFG |
Greece | INCLAUD 100 mg tablets |
Romania | VELYN 100 mg tablets |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.